EG27000A - Process for the preparation of ibodutant (MEN15596) and related intermediates - Google Patents

Process for the preparation of ibodutant (MEN15596) and related intermediates

Info

Publication number
EG27000A
EG27000A EG2011111951A EG2011111951A EG27000A EG 27000 A EG27000 A EG 27000A EG 2011111951 A EG2011111951 A EG 2011111951A EG 2011111951 A EG2011111951 A EG 2011111951A EG 27000 A EG27000 A EG 27000A
Authority
EG
Egypt
Prior art keywords
men15596
ibodutant
preparation
related intermediates
intermediates
Prior art date
Application number
EG2011111951A
Other languages
English (en)
Inventor
Fabrizio Bonaccorsi
Valentina Fedi
Danilo Gianotti
Original Assignee
Malesci Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Malesci Sas filed Critical Malesci Sas
Application granted granted Critical
Publication of EG27000A publication Critical patent/EG27000A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EG2011111951A 2009-05-21 2011-11-17 Process for the preparation of ibodutant (MEN15596) and related intermediates EG27000A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2009A000897A IT1394304B1 (it) 2009-05-21 2009-05-21 Processo per la preparazione di ibodutant (men15596) e relativi intermedi
PCT/EP2010/002884 WO2010133306A1 (en) 2009-05-21 2010-05-11 Process for the preparation of ibodutant (men15596) and related intermediates

Publications (1)

Publication Number Publication Date
EG27000A true EG27000A (en) 2015-03-23

Family

ID=41264221

Family Applications (1)

Application Number Title Priority Date Filing Date
EG2011111951A EG27000A (en) 2009-05-21 2011-11-17 Process for the preparation of ibodutant (MEN15596) and related intermediates

Country Status (29)

Country Link
US (1) US8431684B2 (el)
EP (1) EP2432778B1 (el)
JP (1) JP5645926B2 (el)
KR (1) KR101695346B1 (el)
CN (1) CN102428081B (el)
AR (1) AR076785A1 (el)
AU (1) AU2010251514B2 (el)
BR (1) BRPI1013073A2 (el)
CA (1) CA2762625A1 (el)
CY (1) CY1114079T1 (el)
DK (1) DK2432778T3 (el)
EA (1) EA019777B1 (el)
EG (1) EG27000A (el)
ES (1) ES2409705T3 (el)
HK (1) HK1169828A1 (el)
HR (1) HRP20130380T1 (el)
IL (1) IL216400A (el)
IT (1) IT1394304B1 (el)
MA (1) MA33375B1 (el)
MX (1) MX2011012317A (el)
NZ (1) NZ596523A (el)
PL (1) PL2432778T3 (el)
PT (1) PT2432778E (el)
SG (1) SG176171A1 (el)
SI (1) SI2432778T1 (el)
TW (1) TWI424996B (el)
UA (1) UA105523C2 (el)
WO (1) WO2010133306A1 (el)
ZA (1) ZA201108483B (el)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY130373A (en) * 2001-10-29 2007-06-29 Malesci Sas Linear basic compounds having nk-2 antagonist activity and formulations thereof
ITFI20040221A1 (it) * 2004-10-27 2005-01-27 Guidotti & C Spa Composizioni farmaceutiche a base di nk2 antagonisti per uso pediatrico
US8829209B2 (en) * 2006-01-11 2014-09-09 Seikagaku Corporation Cycloalkylcarbonylamino acid ester derivative and process for producing the same

Also Published As

Publication number Publication date
TW201100406A (en) 2011-01-01
WO2010133306A8 (en) 2011-02-03
NZ596523A (en) 2013-07-26
PT2432778E (pt) 2013-06-03
DK2432778T3 (da) 2013-05-27
EP2432778A1 (en) 2012-03-28
JP2012527410A (ja) 2012-11-08
EP2432778B1 (en) 2013-03-20
SI2432778T1 (sl) 2013-05-31
TWI424996B (zh) 2014-02-01
WO2010133306A1 (en) 2010-11-25
IL216400A (en) 2014-07-31
US20120065370A1 (en) 2012-03-15
MX2011012317A (es) 2012-03-07
CN102428081A (zh) 2012-04-25
UA105523C2 (uk) 2014-05-26
ZA201108483B (en) 2013-01-30
AU2010251514B2 (en) 2014-06-12
EA201190267A1 (ru) 2012-05-30
BRPI1013073A2 (pt) 2016-04-05
EA019777B1 (ru) 2014-06-30
CN102428081B (zh) 2014-09-17
ITMI20090897A1 (it) 2010-11-22
IT1394304B1 (it) 2012-06-06
HRP20130380T1 (hr) 2013-05-31
HK1169828A1 (en) 2013-02-08
SG176171A1 (en) 2011-12-29
MA33375B1 (fr) 2012-06-01
PL2432778T3 (pl) 2013-08-30
CA2762625A1 (en) 2010-11-25
KR20120023675A (ko) 2012-03-13
IL216400A0 (en) 2012-01-31
US8431684B2 (en) 2013-04-30
JP5645926B2 (ja) 2014-12-24
AR076785A1 (es) 2011-07-06
KR101695346B1 (ko) 2017-01-12
ES2409705T3 (es) 2013-06-27
CY1114079T1 (el) 2016-07-27
AU2010251514A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
IL215999A0 (en) Processes for the preparation of rivaroxaban and intermediates thereof
ZA201202504B (en) Process for the preparation of calcobutrol
EP2444398A4 (en) NEW INTERMEDIATE PRODUCTS FROM VORICONAZOLE AND PRODUCTION PROCESS FOR VORICONAZOLE THEREWITH
PL390042A1 (pl) Sposób wytwarzania kwasu chlebowego
HK1169396A1 (en) Improved process for the preparation of ambrisentan and novel intermediates thereof
IL216650A0 (en) Process for the preparation and purification of etravirine and intermediates thereof
IL219913A (en) A process for preparing tapentadol and its intermediates
EP2528923A4 (en) METHOD FOR PRODUCING DARUNAVIR AND DARUNAVIR INTERMEDIATE PRODUCTS
IL214906A (en) A process for making Iwan
SI2189442T1 (sl) Postopek in intermediati za pripravo aliskirena
HK1165408A1 (en) Process for the preparation of 1-benzyl-3-hydroxymethyl-1h-indazole and its derivatives and required magnesium intermediates 1--3--1h-
PL388931A1 (pl) Sposób otrzymywania fluorokarbofunkcyjnych silseskwioksanów
IL217460A0 (en) Novel process for the preparation of 4-aminobut-2-enolides
EG27000A (en) Process for the preparation of ibodutant (MEN15596) and related intermediates
PL2462154T3 (pl) Nowa krystaliczna postać CDB-4124 i sposób jej wytwarzania
IL220160A (en) A process for the preparation of defrasirox
PL389568A1 (pl) Sposób otrzymywania 2-metyloglicydolu
PL388933A1 (pl) Sposób otrzymywania fluorosilikonów
PL388950A1 (pl) Sposób wytwarzania polikaprolaktonu